CoChat

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease

Open access
Telen, Marilyn J. · 2016 · Blood
Cited by 135

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief. However, elucidation of the multiple pathophysiologic mechanisms leading to vaso-occlusion and tissue injury in SCD has now resulted in a burgeoning effort to identify new treatment modalities to prevent or ameliorate the consequences of the disease. Development of new drugs as well as investigation of drugs previously used in other settings have targeted cell adhesion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, coagulation, and platelet activation. Although these efforts have not yet yielded drugs ready for FDA approval, several early studies have been extremely encouraging. Moreover, the marked increase in clinical pharmaceutical research addressing SCD and the new and old drugs in the pipeline make it reasonable to expect that we will soon have new treatments for SCD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-09-618553

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 84

  1. Telen, 2008, It really IS the red cell., Blood, 112, 459, 10.1182/blood-2008-05-155754 · doi:10.1182/blood-2008-05-155754
  2. Pawloski, 2005, Impaired vasodilation by red blood cells in sickle cell disease., Proc Natl Acad Sci USA, 102, 2531, 10.1073/pnas.0409876102 · DOI · Paper page
  3. Sabina, 2009, Ca2+-CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes., Br J Haematol, 144, 434, 10.1111/j.1365-2141.2008.07473.x · DOI
  4. Kuypers, 2014, Hemoglobin s polymerization and red cell membrane changes., Hematol Oncol Clin North Am, 28, 155, 10.1016/j.hoc.2013.12.002 · DOI
  5. Chen, 2008, The genomic analysis of erythrocyte microRNA expression in sickle cell diseases., PLoS One, 3, e2360, 10.1371/journal.pone.0002360 · DOI · Paper page
  6. Sangokoya, 2010, microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease., Blood, 116, 4338, 10.1182/blood-2009-04-214817 · DOI · Paper page
  7. Zennadi, 2012, Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium., Blood, 119, 1217, 10.1182/blood-2011-03-344440 · DOI
  8. Zennadi, 2004, Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions., Blood, 104, 3774, 10.1182/blood-2004-01-0042 · DOI · Paper page
  9. Gauthier, 2005, Protein kinase A-dependent phosphorylation of Lutheran/basal cell adhesion molecule glycoprotein regulates cell adhesion to laminin alpha5., J Biol Chem, 280, 30055, 10.1074/jbc.M503293200 · doi:10.1074/jbc.m503293200
  10. Hines, 2003, Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion., Blood, 101, 3281, 10.1182/blood-2001-12-0289 · DOI · Paper page
  11. Zennadi, 2008, Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium., Blood, 112, 3474, 10.1182/blood-2008-01-134346 · DOI · Paper page
  12. Shiu, 2000, Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells., Blood, 95, 3232, 10.1182/blood.V95.10.3232 · DOI · Paper page
  13. Shaked, 2011, Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry., J Biomed Opt, 16, 030506, 10.1117/1.3556717 · DOI
  14. Burnette, 2011, RNA aptamer therapy for vaso-occlusion in sickle cell disease., Nucleic Acid Ther, 21, 275, 10.1089/nat.2010.0270 · DOI
  15. Matsui, 2001, P-selectin mediates the adhesion of sickle erythrocytes to the endothelium., Blood, 98, 1955, 10.1182/blood.V98.6.1955 · DOI · Paper page
  16. Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest, 106, 411, 10.1172/JCI9225 · DOI · Paper page
  17. Mandarino, 2013, Placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose, healthy subject study of intravenous-administered SelG1, a humanized anti-P-selectin antibody in development for sickle cell disease [abstract]., Blood, 122
  18. Gutsaeva, 2011, Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease., Blood, 117, 727, 10.1182/blood-2010-05-285718 · DOI · Paper page
  19. Batchvarova, 2013, Sevuparin reduces adhesion of both sickle red cells and leukocytes to endothelial cells In vitro and inhibits vaso-occlusion in vivo [abstract]., Blood, 122, 10.1182/blood.V122.21.182.182 · DOI
  20. Leitgeb, 2011, Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates., Am J Trop Med Hyg, 84, 390, 10.4269/ajtmh.2011.10-0256 · DOI
  21. Qari, 2007, Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial., Thromb Haemost, 98, 392, 10.1160/Th06-12-0718 · DOI · Paper page
  22. van Zuuren, 2013, Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease., Cochrane Database Syst Rev, 6, CD010155
  23. De Castro, 2012, Effect of propranolol as antiadhesive therapy in sickle cell disease., Clin Transl Sci, 5, 437, 10.1111/cts.12005 · DOI
  24. Zennadi, 2014, MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo., PLoS One, 9, e110306, 10.1371/journal.pone.0110306 · DOI
  25. Emanuele, 1998, FLOCOR: a new anti-adhesive, rheologic agent., Expert Opin Investig Drugs, 7, 1193, 10.1517/13543784.7.7.1193 · doi:10.1517/13543784.7.7.1193
  26. Ballas, 2004, Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome., Hemoglobin, 28, 85, 10.1081/HEM-120035919 · DOI
  27. Adams-Graves, 1997, RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study., Blood, 90, 2041, 10.1182/blood.V90.5.2041 · DOI
  28. Orringer, 2001, Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial., JAMA, 286, 2099, 10.1001/jama.286.17.2099 · DOI · Paper page
  29. Cheung, 2004, Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study., J Investig Med, 52, 402, 10.1136/jim-52-06-35 · DOI
  30. Hebbel, 2014, Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain., Hematol Oncol Clin North Am, 28, 181, 10.1016/j.hoc.2013.11.005 · DOI
  31. Wallace, 2009, NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-γ and CXCR3 chemokines., Blood, 114, 667, 10.1182/blood-2009-02-205492 · DOI · Paper page
  32. Field, 2011, Targeting iNKT cells for the treatment of sickle cell disease., Clin Immunol, 140, 177, 10.1016/j.clim.2011.03.002 · DOI
  33. Wallace, 2010, Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease., Blood, 116, 5010, 10.1182/blood-2010-06-290643 · DOI · Paper page
  34. Nowak, 2010, The A2aR adenosine receptor controls cytokine production in iNKT cells., Eur J Immunol, 40, 682, 10.1002/eji.200939897 · DOI
  35. Linden, 2011, Regulation of leukocyte function by adenosine receptors., Adv Pharmacol, 61, 95, 10.1016/B978-0-12-385526-8.00004-7 · DOI · Paper page
  36. Zhang, 2012, Adenosine signaling in normal and sickle erythrocytes and beyond., Microbes Infect, 14, 863, 10.1016/j.micinf.2012.05.005 · DOI
  37. Field, 2013, Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson., Blood, 121, 3329, 10.1182/blood-2012-11-465963 · DOI · Paper page
  38. Field, 2013, A Phase I single ascending dose study of NKTT120 in stable adult sickle cell patients [abstract]., Blood, 122, 10.1182/blood.V122.21.977.977 · doi:10.1182/blood.v122.21.977.977
  39. Knight-Perry, 2009, Leukotriene pathway in sickle cell disease: a potential target for directed therapy., Expert Rev Hematol, 2, 57, 10.1586/17474086.2.1.57 · DOI
  40. Field, 2009, Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease., Am J Hematol, 84, 231, 10.1002/ajh.21370 · DOI
  41. Patel, 2009, Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease., Blood, 113, 1129, 10.1182/blood-2008-07-169821 · DOI
  42. Elmariah, 2014, Factors associated with survival in a contemporary adult sickle cell disease cohort., Am J Hematol, 89, 530, 10.1002/ajh.23683 · DOI · Paper page
  43. Kato, 2005, Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality., Br J Haematol, 130, 943, 10.1111/j.1365-2141.2005.05701.x · DOI · Paper page
  44. Haynes, 2006, Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells., Am J Physiol Heart Circ Physiol, 291, H1679, 10.1152/ajpheart.00256.2006 · DOI
  45. Kuvibidila, 2005, Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia., Cytokine, 30, 213, 10.1016/j.cyto.2005.01.010 · DOI
  46. Haynes, 2004, Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway., Blood, 103, 3945, 10.1182/blood-2003-08-2969 · DOI
  47. Chang, 2008, Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion., Blood, 111, 915, 10.1182/blood-2007-04-084061 · DOI · Paper page
  48. Turhan, 2004, Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes., Blood, 103, 2397, 10.1182/blood-2003-07-2209 · DOI · Paper page
  49. Jang, 2012, Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1., Circ Res, 110, 1057, 10.1161/CIRCRESAHA.112.266411 · DOI · Paper page
  50. Manwani, 2015, Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis., Am J Hematol, 90, 381, 10.1002/ajh.23956 · DOI
  51. Hoppe, 2011, A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction., Br J Haematol, 153, 655, 10.1111/j.1365-2141.2010.08480.x · DOI
  52. Charache, 1996, Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent., Medicine (Baltimore), 75, 300, 10.1097/00005792-199611000-00002 · DOI · Paper page
  53. Hebbel, 2010, The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice., Blood, 115, 2483, 10.1182/blood-2009-02-204990 · DOI · Paper page
  54. Reid, 2014, A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 89, 709, 10.1002/ajh.23725 · DOI · Paper page
  55. Kutlar, 2013, A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 88, E255, 10.1002/ajh.23533 · DOI
  56. Kutlar, 2012, A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease., Am J Hematol, 87, 1017, 10.1002/ajh.23306 · DOI
  57. Okam, 2015, Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea., Blood, 125, 3668, 10.1182/blood-2015-03-635391 · DOI
  58. Ikuta, 1998, Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis., Ann N Y Acad Sci, 850, 87, 10.1111/j.1749-6632.1998.tb10466.x · DOI
  59. Atweh, 1999, Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease., Blood, 93, 1790
  60. Meiler, 2011, Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice., Blood, 118, 1109, 10.1182/blood-2010-11-319137 · DOI · Paper page
  61. Moutouh-de Parseval, 2008, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells., J Clin Invest, 118, 248, 10.1172/JCI32322 · DOI · Paper page
  62. Kutlar, 2013, Pomalidomide in sickle cell disease: Phase I study of a novel anti-switching agent [abstract]., Blood, 122, 10.1182/blood.V122.21.777.777 · doi:10.1182/blood.v122.21.777.777
  63. Fard, 2013, Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders., Int J Hematol Oncol Stem Cell Res, 7, 47
  64. Ataga, 2006, Dose-escalation study of ICA-17043 in patients with sickle cell disease., Pharmacotherapy, 26, 1557, 10.1592/phco.26.11.1557 · DOI
  65. Ataga, 2011, Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)., Br J Haematol, 153, 92, 10.1111/j.1365-2141.2010.08520.x · DOI · Paper page
  66. Ataga, 2008, Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia., Blood, 111, 3991, 10.1182/blood-2007-08-110098 · DOI · Paper page
  67. Ataga, 2009, Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia., Expert Opin Investig Drugs, 18, 231, 10.1517/13543780802708011 · DOI
  68. Stocker, 2003, ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice., Blood, 101, 2412, 10.1182/blood-2002-05-1433 · DOI · Paper page
  69. Misra, 2014, PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial., Artif Organs, 38, 702, 10.1111/aor.12341 · DOI
  70. Belcher, 2013, MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice., Blood, 122, 2757, 10.1182/blood-2013-02-486282 · DOI · Paper page
  71. Abdulmalik, 2005, 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells., Br J Haematol, 128, 552, 10.1111/j.1365-2141.2004.05332.x · DOI · Paper page
  72. Ataga, 2007, Hypercoagulability in sickle cell disease: new approaches to an old problem., Hematology Am Soc Hematol Educ Program, 2007, 91, 10.1182/asheducation-2007.1.91 · DOI · Paper page
  73. Ataga, 2003, Hypercoagulability in sickle cell disease: a curious paradox., Am J Med, 115, 721, 10.1016/j.amjmed.2003.07.011 · DOI · Paper page
  74. Babiker, 1987, Coagulation changes in sickle cell disease in early childhood., Acta Haematol, 77, 156, 10.1159/000205981 · doi:10.1159/000205981
  75. Francis, 1991, Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion., Blood Coagul Fibrinolysis, 2, 341, 10.1097/00001721-199104000-00018 · DOI · Paper page
  76. Shah, 2012, Characterization of the hypercoagulable state in patients with sickle cell disease., Thromb Res, 130, e241, 10.1016/j.thromres.2012.08.307 · DOI
  77. Salvaggio, 1963, Long-term anti-coagulation in sickle-cell disease. A clinical study., N Engl J Med, 269, 182, 10.1056/NEJM196307252690403 · DOI
  78. Ahmed, 2004, Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report., Eur J Haematol, 72, 213, 10.1111/j.0902-4441.2003.00209.x · doi:10.1111/j.0902-4441.2003.00209.x
  79. Shah, 2013, Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]., Blood, 122, 10.1182/blood.V122.21.2241.2241 · doi:10.1182/blood.v122.21.2241.2241
  80. Wun, 1999, Platelet-erythrocyte adhesion in sickle cell disease., J Investig Med, 47, 121
  81. Brittain, 2008, Fibronectin bridges monocytes and reticulocytes via integrin α4β1., Br J Haematol, 141, 872, 10.1111/j.1365-2141.2008.07056.x · DOI · Paper page
  82. Lee, 2007, Phase I study of eptifibatide in patients with sickle cell anaemia., Br J Haematol, 139, 612, 10.1111/j.1365-2141.2007.06787.x · DOI · Paper page
  83. Desai, 2013, A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease., Thromb Res, 132, 341, 10.1016/j.thromres.2013.08.002 · DOI
  84. Ohno, 2014, Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel., Thromb Res, 134, 889, 10.1016/j.thromres.2014.07.035 · DOI

Cited by

See all 135

Metadata

Authors
Telen, M. J.
Venue
Blood
Published
2016-02-18
Volume
127
Issue
7
Pages
810-819
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2339933044
Cited by
135
References
6
FWCI
13.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. https://app.cochat.ai/papers/10.1182/blood-2015-09-618553
The paper
Telen, M. J. (2016). Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. https://doi.org/10.1182/blood-2015-09-618553

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.